Mylan Pradaxa Generic Delayed In Boehringer Patent Deal
Mylan Pharmaceuticals Inc. has agreed to hold off on its generic version of Boehringer Ingelheim's blockbuster blood thinner Pradaxa as part of a patent infringement settlement cleared Friday by a New...To view the full article, register now.
Already a subscriber? Click here to view full article